Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

Skip to main content

Table 2 Descriptive findings across four key care junctures in mBC (N = 460)

From: Assessing equity of care across metastatic breast cancer treatment junctures: a multi-site retrospective cohort study

Care Juncture

Receipt of Service

Time to Receipt of Service

(in Days)

 

N (%)

Mean (SD)

Median (Range)

Diagnosis and Evaluation

 Evaluation and Management (E&M) Visit

460 (100.0)

17.1 (18.2)

11.0 (0-211)

Treatment Plan Design

 Treatment Plan

421 (91.5)

26.2 (41.4)

17.0 (0-642)

 Distress Screening

397 (86.3)

820.2 (464.1)

841.0 (0-2017)

Treatment Implementation

 Anticancer Therapy Start

419 (91.1)

39.4 (75.1)

26.0 (0-1022)

 Radiation Start

82 (17.8)

51.6 (142.1)

22.0 (0-1201)

 Surgery Start

51 (11.1)

398.4 (406.9)

223 (0-1491)

 Advance Care Planning (ACP) Visit

152 (33.0)

479.2 (628.6)

98.0 (0-2107)

End of Life Care

 Palliative Care Referral

14 (3.0)

1362.9 (452.4)

1383.5 (6-1796)

 Hospice Enrollment

157 (34.1)

709.6 (465.1)

611.0 (16-2030)

 Hospice Length of Stay (LOS)a

N/A

32.0 (34.0)

17.5 (2-146)

 Chemotherapy within 14 days of deathb

21 (8.5)

N/A

N/A

  1. aN = 92 based on those who have a record of both ‘hospice enrollment’ and ‘death,’ (n = 146) and information about hospice length of stay (LOS)
  2. bN = 247 based on those who have a record of both ‘death’ (n = 250) and information about whether or not they received chemotherapy within 14 days of death